Search
Invivyd Inc
IVVDAdd to Watchlist
0.894USD
+0.039+4.61%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
252.77MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.61%
5 Days
+0.24%
1 Month
-19.48%
6 Months
-64.25%
Year to Date
-63.81%
1 Year
+21.59%
Key Figures
0.839Open
0.907High
2.20MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.78%Turnover Ratio
0.854Prev. Close
0.839Low
1.48MTurnover
LossP/E Static
1.24P/B
0.00%Div Yield TTM
-44.92%ROA
3.07052wk High
0.46Volume Ratio
-169.93MNet Profit
282.80MShares
-0.3026EPS TTM
0.65Beta
-60.34%ROE
0.48352wk Low
7.89%Amplitude
92.49%Gross Margin
252.77MMarket Cap
-3.78Reward/Risk
6.10%Risk Rate
TradingKey Stock Score of Invivyd Inc
Currency: USD Updated: 2026-07-02Key Insights
Invivyd Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 73 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Invivyd Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Invivyd Inc Highlights
StrengthsRisks
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Growing
The company is in a growing phase, with the latest annual income totaling USD 53.43M.
Undervalued
The company’s latest PE is -2.95, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 272.04M shares, increasing 13.10% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 21.82M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.40.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
10.000
Target Price
+1070.41%
Upside Space
Invivyd Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Invivyd Inc Info
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Ticker SymbolIVVD
CompanyInvivyd Inc
CEO
Websitehttps://invivyd.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Invivyd Inc (IVVD)?
The current price of Invivyd Inc (IVVD) is 0.89.
What is the symbol of Invivyd Inc?
The ticker symbol of Invivyd Inc is IVVD.
What is the 52-week high of Invivyd Inc?
The 52-week high of Invivyd Inc is 3.07.
What is the 52-week low of Invivyd Inc?
The 52-week low of Invivyd Inc is 0.48.
What is the market capitalization of Invivyd Inc?
The market capitalization of Invivyd Inc is 252.77M.
Is Invivyd Inc (IVVD) currently rated as Buy, Hold, or Sell?
According to analysts, Invivyd Inc (IVVD) has an overall rating of Buy, with a price target of 10.00.
What is the Earnings Per Share (EPS TTM) of Invivyd Inc (IVVD)?
The Earnings Per Share (EPS TTM) of Invivyd Inc (IVVD) is -0.30.